7 results

• Study Questions Whether Side Effects of Xeljanz, Similar Drugs, Increase Blood Clot Risks

  September 8, 2022

  Irvin Jackson

  A new study raises doubts about whether Xeljanz and similar drugs increase the risk of blood clots.

• Skin Cancer Risk Linked to Xeljanz, Jakafi, Other JAK Inhibitors: Study

  May 18, 2022

  Irvin Jackson

  A new study links Xeljanz and similar drugs to an increased risk of skin cancer.

• Opzelura Eczema Cream Investigation Announced Over Texture Problems

  November 4, 2021

  Irvin Jackson

  The eczema cream Opzelura, made from the same active ingredient as Jakafi, is being investigated for texture issues as the entire class of drugs faces scrutiny over heart and cancer risks.

• Experts, FDA Concerned Xeljanz Heart and Cancer Problems May Affect Similar Arthritis Drugs

  July 28, 2021

  Irvin Jackson

  Drugs in the same class as Xeljanz face increased scrutiny over concerns they may carry similar heart and cancer risks such as those suspected of plaguing the arthritis drug.

• FDA Worried Jakafi May Have Cancer, Heart Risks Similar to Xeljanz

  June 10, 2021

  Irvin Jackson

  The FDA has delayed an expanded approval for the drug Jakafi, potentially due to concerns over heart and cancer risks linked to Pfizer's Xeljanz, a similar drug.

• Jakafi Risks Require Monitoring of Dose During First Three Months: Study

  December 30, 2013

  Irvin Jackson

  Doctors should closely monitor Jakafi patients for the first three months for signs of anemia, according to a new study.

• Jakafi Side Effects May Be Linked to PML Brain Disease: Report

  July 12, 2013

  Irvin Jackson

  The bone marrow disease drug Jakafi may be linked to a rare and often deadly brain disease known as PML, according to a U.K. case study.